西格列汀对糖尿病合并肾损伤患者肾功能及γ-谷氨酰转移酶的影响  

Effects of sitagliptin on renal function and gamma-glutamyltransferase in diabetes combined with kidney injury

作　　者：应俊[1,2] 张晓辉[1] 陈江华[1] 陈光明[2] 

机构地区：[1]浙江大学医学院附属第一医院肾内科,浙江杭州310003 [2]金华市中心医院,浙江金华321000

出　　处：《中国新药与临床杂志》2016年第4期273-276,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的观察西格列汀对糖尿病合并肾损害患者肾功能及γ-谷氨酰转移酶(γ-GT)等指标的影响。方法选择早期2型糖尿病合并肾损伤且血糖控制不佳的患者67例,随机分为两组,西格列汀组32例,对照组35例。在原治疗方案的基础上,西格列汀组加用西格列汀片100 mg,每日1次;对照组可增加药物剂量或联合除二肽基肽酶4抑制剂外的降糖药物。观察时间均为12周。治疗前后检测患者空腹血糖(FPG)、糖化血红蛋白(Hb A_(1c))、β_2微球蛋白(β_2-MG)、血尿素氮(BUN)、胱抑素C(Cys C)、血肌酐(Cr)、γ-GT水平,并观察不良反应发生情况。结果治疗前两组各项指标比较差异均无显著意义(P>0.05)。治疗12周后,两组FPG和Hb A1c均下降,与治疗前比较差异显著(P<0.05),组间比较无显著差异(P>0.05)。对照组Cr、BUN、β_2-MG、Cys C、γ-GT无明显变化(P>0.05),而西格列汀组以上指标均降低(P<0.05),且低于对照组(P<0.05)。两组均无明显不良反应发生。结论西格列汀治疗糖尿病合并肾损害患者,可以降低γ-GT等指标,改善肾功能。AIM To evaluate the clinical effects of sitagliptin on renal function of diabetes in combination with kidney injury and its influence on gamma- glutamyltransferase（γ-GT）. METHODS Sixty- seven diabetes in combination with kidney injury patients, and their blood glucose had been poorly controlled, were randomly divided into two groups： the sitagliptin group（n= 32） and control group（ n=35）. The patients in the sitagliptin group were treated with sitagliptin 100 mg·d^（-1） based on the original treatment and the patients in the control group were treated with increasing dose of the original hypoglycemic agents or combined with other hypoglycemic agents except dipeptidyl peptidase 4. Observe time was 12 weeks. The levels of fasting plasma glucose （FPG）, glycosylated hemoglobin（ Hb A_（1c））, β_2 microglobulin（ β_2-MG）, cystatin C（ Cys C）, serum creatinine（ Cr）, blood urea nitrogen（ BUN） and γ-GT were tested before and after the treatment. And the adverse drug reactions were observed. RESULTS There were no significant difference in all indicators between the two groups before the treatment（ P〉 0.05）. FPG and Hb A_（1c） decreased in both groups after 12 wk treatment, with significant difference compared with those before the treatment（ P〈0.05）, and there was no significant difference between two groups（P〉 0.05）. The levels of Cr, BUN, β_2-MG, Cys C and γ-GT of the control group have no significant change（ P 〉0.05）. While above indexes in the sitagliptin group were reduced significantly（P〈 0.05） and were lower than those of the control group（P 〈0.05）. No obvious adverse reactions occurred in both groups. CONCLUSION The treatment of sitagliptin for diabetes in combination with kidney injury can reduce the indices such as γ-GT and improve renal function.

关 键 词：西格列汀 糖尿病 Γ-谷氨酰转移酶 肾损伤 

分 类 号：R977[医药卫生—药品]